Experimental monoclonal antibodies can coax aggressive prostate and breast cancers into submission, finds research

Therapeutic antibodies that cause aggressive tumors to become susceptible to treatment are being studied with the hope of one day changing the fate of patients who either relapse soon after cancer therapy or whose stubborn tumors repel potent medications rendering the drugs useless.

Leave A Comment

Your email address will not be published. Required fields are marked *